Skip to main content
Erschienen in: Skeletal Radiology 4/2003

01.04.2003 | Newer Technology

18FDG PET scanning of benign and malignant musculoskeletal lesions

verfasst von: Frieda Feldman, Ronald van Heertum, Chitra Manos

Erschienen in: Skeletal Radiology | Ausgabe 4/2003

Einloggen, um Zugang zu erhalten

Abstract

Objective

To describe the technique, applications and advantages of 18FDG PET scanning in detection, analysis and management of musculoskeletal lesions.

Design and patients

Forty-five patients (19 males,26 females) aged 9 to 81 years had radiographs, routine radionuclide scans, CT and/or MRI of clinically suspected active benign or malignant musculoskeletal lesions. 18FDG scans with a Siemens ECAT EXACT 921 dedicated PET unit (Knoxville, Tenn.) and FWH=6 mm images acquired as a 5–6 bed examination (6 min emission and 4 min transmission) used OSEM iterative reconstruction with segmented transmission attenuation correction and a Gaussian filter (cutoff 6.7 mm). Region of interest (ROI) 3×3 pixel image analysis based on transverse whole body images (slice thickness 3.37 mm) generated Maximum Standard Uptake Values (Max SUV) with a cutoff of 2.0 used to distinguish benign and malignant lesions.

Results

Thirty-nine studies were available for SUV ROI analysis. Overall sensitivity for differentiating malignant from benign osseous and non-osseous lesions was 91.7% (22/24), overall specificity was 100% (11/11) with an accuracy of 91.7%. All aggressive lesions had a Max SUV >2.0. Data separating benign from malignant lesions and aggressive from benign lesions were statistically significant (P<0.001) in both categories. There was no statistically significant difference in distinguishing aggressive from malignant lesions (P, ns).

Conclusion

18FDG PET contributes unique information regarding metabolism of musculoskeletal lesions. By supplying a physiologic basis for more informed treatment and management, it influences prognosis and survival. Moreover, since residual, recurrent or metastatic tumors can be simultaneously documented on a single whole body scan, PET may theoretically prove to be cost-effective.
Literatur
1.
Zurück zum Zitat Blau M, Nagler W, Bender MA. Fluorine-18 a new isotope for bone scanning. J Nucl Med 1962; 3:332–334. Blau M, Nagler W, Bender MA. Fluorine-18 a new isotope for bone scanning. J Nucl Med 1962; 3:332–334.
2.
Zurück zum Zitat Som P, Atkins, HL, Bandaypadhyay D, et al. A fluorinated glucose analog, 2-fluoro-2-glucose (F18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980; 21:670–675.PubMed Som P, Atkins, HL, Bandaypadhyay D, et al. A fluorinated glucose analog, 2-fluoro-2-glucose (F18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980; 21:670–675.PubMed
3.
Zurück zum Zitat Warburg O. The metabolism of tumors. London: Constable, 1930:75–327. Warburg O. The metabolism of tumors. London: Constable, 1930:75–327.
4.
Zurück zum Zitat Schulte M, Brecht-Krauss D, Heymer B, et al. Grading of tumors and tumor-like lesions of bone: evaluation by FDG PET. J Nucl Med. 2000; 41:1695–1701. Schulte M, Brecht-Krauss D, Heymer B, et al. Grading of tumors and tumor-like lesions of bone: evaluation by FDG PET. J Nucl Med. 2000; 41:1695–1701.
5.
Zurück zum Zitat Aoki J, Watanabe H, Shinozaki T, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology 2001; 219:774–777.PubMed Aoki J, Watanabe H, Shinozaki T, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology 2001; 219:774–777.PubMed
6.
Zurück zum Zitat Schirrmeister H, Guhlmann A, Elsner K, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus18F PET. J Nucl Med. 1999;40:1623–1629. Schirrmeister H, Guhlmann A, Elsner K, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus18F PET. J Nucl Med. 1999;40:1623–1629.
7.
Zurück zum Zitat Sasaki M, Ichiya Y, Kuwabara Y, et al. Fluorine-18 fluorodeoxglucose positron emission tomography in technetium 99m hydroxymethylenediphosphate negative bone tumors. J Nucl Med 1993; 34:288–290.PubMed Sasaki M, Ichiya Y, Kuwabara Y, et al. Fluorine-18 fluorodeoxglucose positron emission tomography in technetium 99m hydroxymethylenediphosphate negative bone tumors. J Nucl Med 1993; 34:288–290.PubMed
8.
Zurück zum Zitat Garcia R, Kim EE, Wong FC, et al. Comparison of fluorine-18 FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas. J Nucl Med 1996; 37:1476–1479.PubMed Garcia R, Kim EE, Wong FC, et al. Comparison of fluorine-18 FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas. J Nucl Med 1996; 37:1476–1479.PubMed
9.
Zurück zum Zitat Abdel-Dayem HM. The role of nuclear medicine in primary bone and soft tissue tumors. Semin Nucl Med. 1997; 27:355–363. Abdel-Dayem HM. The role of nuclear medicine in primary bone and soft tissue tumors. Semin Nucl Med. 1997; 27:355–363.
10.
Zurück zum Zitat Kole AC, Nieweg OE, VanGinkel RJ, Pruim J, et al. Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using 18-F fluorodeoxyglucose. Ann Surg Oncol 1997; 4:57–63.PubMed Kole AC, Nieweg OE, VanGinkel RJ, Pruim J, et al. Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using 18-F fluorodeoxyglucose. Ann Surg Oncol 1997; 4:57–63.PubMed
11.
Zurück zum Zitat Schwartzbach M, Willeke F, Dimitrakopoulou-Strauss A, et al. Functional imaging and detection of local recurrence in soft tissue sarcomas by position emission tomography. Anticancer Res 1999; 19:1343–1350.PubMed Schwartzbach M, Willeke F, Dimitrakopoulou-Strauss A, et al. Functional imaging and detection of local recurrence in soft tissue sarcomas by position emission tomography. Anticancer Res 1999; 19:1343–1350.PubMed
12.
Zurück zum Zitat Kern KA, Brunetti A, Nortn JA, et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 1988; 29:181–186.PubMed Kern KA, Brunetti A, Nortn JA, et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 1988; 29:181–186.PubMed
13.
Zurück zum Zitat Kole AC, Nieweg OE, Hoekstra HJ, et al. Fluorine-18 fluorodeoxyglucose assessment of glucose metabolism in bone tumors. J Nucl Med 1998; 39:810–815.PubMed Kole AC, Nieweg OE, Hoekstra HJ, et al. Fluorine-18 fluorodeoxyglucose assessment of glucose metabolism in bone tumors. J Nucl Med 1998; 39:810–815.PubMed
14.
Zurück zum Zitat Adler LP, Blair HF, Williams RP, et al. Grading liposarcoma with PET using (18F)FDG. J Comput Assist Tomogr 1990; 14:960–962.PubMed Adler LP, Blair HF, Williams RP, et al. Grading liposarcoma with PET using (18F)FDG. J Comput Assist Tomogr 1990; 14:960–962.PubMed
15.
Zurück zum Zitat Adler LP, Blair HF, Makley JT, et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991; 32:1508–1512.PubMed Adler LP, Blair HF, Makley JT, et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991; 32:1508–1512.PubMed
16.
Zurück zum Zitat Nieweg OE, Pruim J, VanGinkle RJ, et al. Fluorine-18 fluorodeoxyglucose PET imaging of soft tissue sarcoma. J Nucl Med 1996; 37:257–261.PubMed Nieweg OE, Pruim J, VanGinkle RJ, et al. Fluorine-18 fluorodeoxyglucose PET imaging of soft tissue sarcoma. J Nucl Med 1996; 37:257–261.PubMed
17.
Zurück zum Zitat Griffeth LK, Dehdashti FD, McGire AH, et al. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-d-glucose. Radiology 1992; 182:185–194.PubMed Griffeth LK, Dehdashti FD, McGire AH, et al. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-d-glucose. Radiology 1992; 182:185–194.PubMed
18.
Zurück zum Zitat Lodge MA, Lucas JD, Marsken PK, et al. A PET study: 18-FDG uptake in soft tissue masses. Eur J Nucl Med 1999; 26:22–30.CrossRefPubMed Lodge MA, Lucas JD, Marsken PK, et al. A PET study: 18-FDG uptake in soft tissue masses. Eur J Nucl Med 1999; 26:22–30.CrossRefPubMed
19.
Zurück zum Zitat Lucas JD, O'Doherthy MJ, Wong JC, et al. Evaluation of fluorodeoxyglucose positron emmision tomography in the management of soft tissue sarcomas. J Bone Joint Surg Br 1998; 80:441–447.PubMed Lucas JD, O'Doherthy MJ, Wong JC, et al. Evaluation of fluorodeoxyglucose positron emmision tomography in the management of soft tissue sarcomas. J Bone Joint Surg Br 1998; 80:441–447.PubMed
20.
Zurück zum Zitat Matthias HM, Schwarzback MD, Dimitrakopoulou-Strauss A, et al. Clinical value of (18F)fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg 2002; 231:380–386. Matthias HM, Schwarzback MD, Dimitrakopoulou-Strauss A, et al. Clinical value of (18F)fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg 2002; 231:380–386.
21.
Zurück zum Zitat Eary JF, Conrad E, Bruckner JD, et al. Quantitative (F-18)fluorodeoxyglucose position emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 1998; 4:1215–1220.PubMed Eary JF, Conrad E, Bruckner JD, et al. Quantitative (F-18)fluorodeoxyglucose position emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 1998; 4:1215–1220.PubMed
22.
Zurück zum Zitat Brudin LH, Valid SO, Rhodes CG, et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med 1994; 21:297–305.PubMed Brudin LH, Valid SO, Rhodes CG, et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med 1994; 21:297–305.PubMed
23.
Zurück zum Zitat Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissue studies by microautoradiography. J Nucl Med 1992; 33:1972–1980.PubMed Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissue studies by microautoradiography. J Nucl Med 1992; 33:1972–1980.PubMed
24.
Zurück zum Zitat Guhlmann A, Brechy-Krauss D, Suger G, et al. Chronic osteomyelitis: detection with FDG PET and correlation with histopathologic findings. Radiology 1998; 206:749–754.PubMed Guhlmann A, Brechy-Krauss D, Suger G, et al. Chronic osteomyelitis: detection with FDG PET and correlation with histopathologic findings. Radiology 1998; 206:749–754.PubMed
25.
Zurück zum Zitat Gamelli RL, Liu H, He L, et al. Augmentation of glucose transporter-1 in macrophages following thermal injury and sepsis in mice. J Leukoc Biol 1996; 59:639–647.PubMed Gamelli RL, Liu H, He L, et al. Augmentation of glucose transporter-1 in macrophages following thermal injury and sepsis in mice. J Leukoc Biol 1996; 59:639–647.PubMed
26.
Zurück zum Zitat Dehdashti FD, Siegel GA, Griffeth LK, et al. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-(F-18)fluoro-2-deoxy-d-glucose. Radiology 1996; 200:243–247.PubMed Dehdashti FD, Siegel GA, Griffeth LK, et al. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-(F-18)fluoro-2-deoxy-d-glucose. Radiology 1996; 200:243–247.PubMed
27.
Zurück zum Zitat Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-(fluorine-18)-fluoro-2-deoxy-d-glucose: variations with body weight and a method for correction. Radiology 1993; 189:847–850.PubMed Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-(fluorine-18)-fluoro-2-deoxy-d-glucose: variations with body weight and a method for correction. Radiology 1993; 189:847–850.PubMed
28.
Zurück zum Zitat Hamberg LM, Hunter GJ, Alpert NM, et al. The dose uptake ratio as an index of glucose metabolism: useful parameter of oversimplification. J Nucl Med 1994; 35:1308–1312.PubMed Hamberg LM, Hunter GJ, Alpert NM, et al. The dose uptake ratio as an index of glucose metabolism: useful parameter of oversimplification. J Nucl Med 1994; 35:1308–1312.PubMed
29.
Zurück zum Zitat Wahl RL, Quint LE, Cieslak D, et al. Anatometabolic tumor imaging: fusion of FDG PET with CT or MRI to localize foci of increased activity. J Nucl Med 1993; 34:1190–1197. Wahl RL, Quint LE, Cieslak D, et al. Anatometabolic tumor imaging: fusion of FDG PET with CT or MRI to localize foci of increased activity. J Nucl Med 1993; 34:1190–1197.
Metadaten
Titel
18FDG PET scanning of benign and malignant musculoskeletal lesions
verfasst von
Frieda Feldman
Ronald van Heertum
Chitra Manos
Publikationsdatum
01.04.2003
Verlag
Springer-Verlag
Erschienen in
Skeletal Radiology / Ausgabe 4/2003
Print ISSN: 0364-2348
Elektronische ISSN: 1432-2161
DOI
https://doi.org/10.1007/s00256-003-0623-3

Weitere Artikel der Ausgabe 4/2003

Skeletal Radiology 4/2003 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

13.04.2024 Klinik aktuell Kongressbericht

Die Teilnehmer eines Forums beim DGIM-Kongress waren sich einig: Fehler in der Medizin sind häufig in ungeeigneten Prozessen und mangelnder Kommunikation begründet. Gespräche mit Patienten und im Team können helfen.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.